← Back to Search

Interleukin

Ipilimumab: Cohort 2 (Ocular) for Melanoma

Phase 2
Waitlist Available
Led By Evidio Domingo-Musibay, MD
Research Sponsored by Masonic Cancer Center, University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately up to 2 years
Awards & highlights

Study Summary

This trial is testing a combination of two immunotherapy drugs to see if they are more effective than one immunotherapy drug alone in treating people with metastatic melanoma that has not responded to other treatments.

Eligible Conditions
  • Metastatic Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Safety and Tolerability of Sequential Combination Immunotherapy (Incidence of Adverse Events)
Safety and Tolerability of Sequential Combination Immunotherapy (Incidence of Stopping Rule Events)
Secondary outcome measures
Overall Survival (OS)
Progression-Free Survival (PFS)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort 2: Nivolumab & IpilimumabExperimental Treatment3 Interventions
Group II: Cohort 1: NivolumabExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ipilimumab: Cohort 2 (Ocular)
2019
Completed Phase 2
~10
Nivolumab: Cohort 2 (Ocular)
2019
Completed Phase 2
~10
Aldesleukin: All Patients
2019
Completed Phase 2
~10
Nivolumab: Cohort 1 (Cutaneous)
2019
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

Masonic Cancer Center, University of MinnesotaLead Sponsor
271 Previous Clinical Trials
14,621 Total Patients Enrolled
3 Trials studying Melanoma
21 Patients Enrolled for Melanoma
Evidio Domingo-Musibay, MDPrincipal InvestigatorDivision of Hematology, Oncology and Transplantation, University of Minnesota

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What other trials have been conducted involving Ipilimumab and the second cohort of patients presenting ocular symptoms?

"At present, there are 89 clinical trials for Ipilimumab: Cohort 2 (Ocular) in Phase 3 with 814 total studies running. Pittsburgh is hosting several of these investigations while the medication can be trialled at 43135 sites worldwide."

Answered by AI

Are there any open enrollment opportunities for this research study?

"The clinicaltrials.gov portal states that this trial, initially posted on May 28th 2019 and last updated in February 25th 2022 is not recruiting any longer, however 1579 other medical trials remain open to participants."

Answered by AI

Could I potentially partake in this clinical research?

"To partake in this trial, participants must possess metastatic melanoma and meet the age requirements of 18 to 80. Currently, 4 patients are needed for inclusion within the study."

Answered by AI

How reliable is cohort two of Ipilimumab in safeguarding public health?

"The safety of Ipilimumab: Cohort 2 (Ocular) was rated a score of 2, as the Phase 2 trial has only provided evidence for its security and not yet demonstrated efficacy."

Answered by AI

Does this trial accept participants below the age of 65?

"This study is accepting individuals aged 18 and up, but below 80 years old."

Answered by AI

What medical conditions is Ipilimumab: Cohort 2 (Ocular) typically prescribed for?

"Typically, Ipilimumab: Cohort 2 (Ocular) is administered to patients with pre-existing antiangiogenic therapy. However, it has been known to be a successful treatment for malignant neoplasms, unresectable melanoma, and squamous cell carcinoma as well."

Answered by AI

How many participants are engaged in this clinical research?

"At present, this clinical trial is not accepting any further candidates. The study was first published on May 28th 2019 and has since been edited as recently as February 25th 2022. Those looking for similar trials may be interested in the 765 studies that are presently recruiting participants with metastatic melanoma or 814 trails currently enrolling individuals with Ipilimumab: Cohort 2 (Ocular)."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Radiation and Combination Immunotherapy for Melanoma
2019. "Radiation and Combination Immunotherapy for Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03850691.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top